Intervention not reported
Multi‐component, education‐based interventions · people who smoke and are involved in the care of young children (birth to 12 years of age)
1 finding from 1 review
Days of unsanctioned opioid use · patients with opioid dependence
1 finding from 1 review
Intervention not reported
Health‐related quality of life (generic) SF‐36 (Physical Component Summary (PCS) score) Scale from 0‐100 Higher value post intervention is favourable, indicating improvement in health‐related quality of life · people with stable COPD
1 finding from 1 review
Intervention not reported
Health‐related quality of life (generic) SF‐36 (Mental Component Sumary (MCS) score) Scale from 0‐100 Higher value post intervention is favourable, indicating improvement in health‐related quality of life · people with stable COPD
1 finding from 1 review
Process outcome, Practitioner Impact 5. Staff did not provide psychological interventions (as suggested by the guideline) · patients with schizophrenia or related psychoses
Re‐written guideline text showed no clear difference in process outcome, Practitioner Impact 5. Staff did not provide… compared with original guideline text (low certainty).
1 finding from 1 review
Intervention not reported
Knowledge (Multi‐component intervention) [mean number of correct questionnaire responses, assessed immediately post‐intervention] · People with a health condition or nominally 'well' considering real clinical trial participation (across a range of topic areas)
1 finding from 1 review
Intervention not reported
Satisfaction with the information provided (Single and multi‐component intervention) · People with a health condition or nominally 'well' considering real clinical trial participation (across a range of topic areas)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Anxiety, or other psychological distress (Single and multi‐component intervention) · People with a health condition or nominally 'well' considering real clinical trial participation (across a range of topic areas)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Retention of knowledge (Single and multi‐component intervention) · People with a health condition or nominally 'well' considering real clinical trial participation (across a range of topic areas)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Satisfaction with the decision‐making process (multi‐component intervention) [questionnaire, assessed immediately post‐intervention] · People with a health condition or nominally 'well' considering real clinical trial participation (across a range of topic areas)
1 finding from 1 review
Intervention not reported
Recurrent pericarditis Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers) Intervention: colchicine with NSAID; Comparison: NSAID alone
The intervention probably leads to lower recurrent pericarditis Chest pain + (ECG changes +/‐… (moderate certainty).
1 finding from 1 review
Intervention not reported
Acute pericarditis Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers) Intervention: colchicine with NSAID; Comparison: NSAID alone
The intervention probably leads to lower acute pericarditis Chest pain + (ECG changes +/‐ echocardiographic… (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal macrovascular outcomes 1. Composite a. Intervention vs metformin [1a. 6 months to 4 years] b. Intervention vs thiazolidinediones [1b. 52 weeks to 4 years] c. Intervention vs meglitinide [1c. 12 months to 15 months]2. Non‐fatal myocardial... · participants with type 2 diabetes mellitus
The intervention may leads to lower non‐fatal macrovascular outcomes 1. Composite a. Intervention vs… (low certainty).
1 finding from 1 review
RR 0.67 [0.48, 0.93]
1 study · 3 participants
Low
Intervention not reported
Cancer a. Intervention vs thiazolidinediones [52 weeks to 4 years] b. Intervention vs insulin [6 years to 10 years] · participants with type 2 diabetes mellitus
The intervention showed no clear difference in cancer a. Intervention vs thiazolidinediones [52 weeks to 4 years]… (low certainty).
1 finding from 1 review
Intervention not reported
Health‐related quality of life a. Intervention vs thiazolidinediones [12 months] b. Intervention vs insulin [6 years] c. Intervention vs alpha‐glucosidase inhibitors [12 months] · participants with type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Adverse events 1. All adverse events 2. Drop‐outs due to adverse events Interventions vs thiazolidinediones [1. 6 months to 12 months] [2. 24 weeks to 52 weeks] · participants with type 2 diabetes mellitus
The intervention may leads to lower adverse events 1. All adverse events 2. Drop‐outs due to adverse… (low certainty).
1 finding from 1 review
RR 0.88 [0.78, 0.99]
1 study · 3 participants
Low
Intervention not reported
All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · participants with type 2 diabetes mellitus
The intervention showed no clear difference in all‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4… (low certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs meglitinide [d. 12 months to 17 m... · participants with type 2 diabetes mellitus
The intervention showed no clear difference in cardiovascular mortality a. Intervention vs metformin [a. 24 weeks… (low certainty).
1 finding from 1 review
Marginal bone level change · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional triamcinolone changes maximal mouth opening (interincisal distance) compared with intralesional triamcinolone plus salvianolic acid B (very low certainty).
1 finding from 1 review